Purple Biotech Regains Nasdaq Listing After 10-Day $1.00 ADS Run
Purple Biotech regained compliance by maintaining a minimum closing ADS price of $1.00 for ten consecutive business days ending March 13, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). This compliance secures its continued listing on the Nasdaq Capital Market and averts potential delisting related to bid price deficiencies.
1. Regained Nasdaq Compliance
Purple Biotech achieved the minimum bid price requirement by maintaining its American Depositary Share closing price at or above $1.00 for ten consecutive business days, reaching the threshold on March 13, 2026 and satisfying Nasdaq Listing Rule 5550(a)(2).
2. Implications for Listing and Operations
By regaining compliance, the company retains its Nasdaq Capital Market listing status and avoids the operational disruptions and investor concerns associated with delisting, allowing management to focus on advancing its masked tri-specific antibody programs IM1240 and IM1305 toward clinical development.